Does Kaiser Permanente Cover Prolia (Denosumab)?

What Is Prolia and Why Is It Prescribed for Osteoporosis?

Prolia is a RANK ligand inhibitor that slows bone resorption by blocking osteoclast formation. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and later for bone loss in men receiving androgen deprivation therapy and women receiving aromatase inhibitor therapy for breast cancer. It is given as a 60 mg subcutaneous injection every 6 months, typically in a physician's office. [1]

The FREEDOM trial (N=7,808) demonstrated that denosumab reduced new vertebral fracture risk by 68% over 36 months compared to placebo, and reduced hip fracture risk by 40% over the same period. [2] Those numbers are among the strongest fracture-reduction data in osteoporosis pharmacotherapy, which is why major guidelines recommend Prolia as a first-line option for patients with severe osteoporosis or who cannot tolerate oral bisphosphonates.

The AACE/ACE 2020 Clinical Practice Guidelines state: "Denosumab is recommended as first-line therapy for postmenopausal women with osteoporosis who are at high or very high risk for fracture, particularly those with renal impairment where oral bisphosphonates may be contraindicated." [3] Unlike oral bisphosphonates, Prolia carries no renal dose-adjustment restriction down to an eGFR of 15 mL/min, making it useful for a broad patient population. [4]

Physicians also prescribe Prolia for glucocorticoid-induced osteoporosis and for bone metastases prevention under the brand name Xgeva (at a higher dose), though Xgeva coverage follows a different pathway. This article focuses exclusively on Prolia 60 mg for osteoporosis indications. [5]

How Kaiser Permanente's Formulary Works

Kaiser Permanente operates as both an insurer and a care delivery system in eight regions: Northern California, Southern California, Colorado, Georgia, Hawaii, Mid-Atlantic States, Northwest, and Washington. Each region maintains its own formulary, though all regions use a tiered drug list that classifies medications as Tier 1 (generic preferred), Tier 2 (preferred brand), Tier 3 (non-preferred brand), or Tier 4 (specialty). [6]

Prolia sits on Tier 3 or Tier 4 in most KP regional formularies as of 2025, reflecting its specialty-drug classification and the absence of a generic denosumab biosimilar approved by the FDA for this indication in the United States. The FDA approved Jubbonti and Wyost (denosumab-bbdz) as biosimilars for Xgeva indications in 2023, but biosimilar versions of Prolia's specific indication set remain under regulatory review. [7]

Because Prolia is typically administered in a physician office or infusion center rather than dispensed at a retail pharmacy, it is billed under the medical benefit rather than the pharmacy benefit in most KP plans. That billing distinction matters. Drugs billed under the medical benefit are subject to your plan's medical deductible and coinsurance rather than your pharmacy copay tier, and the cost calculation differs substantially.

Members who receive Prolia at a KP facility (the standard pathway) generally have the injection billed as a physician office procedure. Under most commercial KP plans, a specialist office visit copay of $30 to $60 applies. Under most KP Medicare Advantage plans, the 2025 Part B cost-sharing rules apply: after the $240 Part B deductible, Medicare pays 80% and the plan covers the remaining 20%, often reducing member cost to $0 under KP Senior Advantage. [8]

Does Kaiser Permanente Require Prior Authorization for Prolia?

Yes. Prior authorization (PA) is required for Prolia in all KP regions as of 2025. PA exists because Prolia is a high-cost specialty biologic, and guidelines reserve it for patients who meet specific clinical thresholds. Knowing those criteria in advance prevents unnecessary delays.

Standard KP prior authorization criteria for Prolia typically include at least one of the following, though exact criteria vary by region and plan year:

A DXA-confirmed T-score of <-2.5 at the lumbar spine, femoral neck, or total hip is the most common qualifying threshold. [9] Patients with a prior fragility fracture (vertebral, hip, or distal radius) may qualify regardless of T-score, particularly if FRAX 10-year major osteoporotic fracture probability exceeds 20% or hip fracture probability exceeds 3%. [10] Patients with documented intolerance or contraindication to oral bisphosphonates (esophageal disease, severe GI upset, inability to remain upright for 30 minutes) qualify under most KP PA criteria without a bisphosphonate trial requirement.

Prescribers submit PA requests through the KP electronic health record system. Members can track PA status through the KP member portal or by calling the regional Member Services line. Denial rates for Prolia are not publicly disclosed by KP, but national payer data suggest first-pass approval rates for denosumab run approximately 70 to 80% when clinical documentation is complete. [11]

If a PA is denied, KP members have the right to appeal under California's Independent Medical Review process (for CA-regulated plans) or under federal appeals rules for Medicare Advantage plans. The AACE guidelines provide strong supporting language for appeals documentation. [3]

What Does Prolia Cost at Kaiser Permanente?

Cost varies by plan type, region, and benefit year. Here is a practical breakdown based on how KP typically structures cost-sharing for office-administered specialty biologics.

Commercial HMO and PPO plans. Prolia is billed as a medical-benefit drug. Most KP commercial members pay their specialist office visit copay ($30 to $60 per injection) once the plan deductible is met. Before the deductible, the member may owe the full contracted rate, which runs $800 to $1,300 per injection for KP-negotiated pricing. Members with a high-deductible health plan should factor two injections per year into out-of-pocket projections.

KP Medicare Advantage (Senior Advantage). Under Part B, Medicare pays 80% of the Medicare-approved amount for Prolia after the $240 annual Part B deductible. KP Senior Advantage plans frequently waive or reduce the remaining 20% coinsurance, bringing member cost to $0 in many plan variants. [8] Confirming your specific 2025 Evidence of Coverage document is necessary, as benefit structures shift annually.

Medi-Cal (Medicaid) through KP. For members enrolled in KP Medi-Cal managed care plans, Prolia is covered with $0 to $3 copay when prior authorization is approved. Medi-Cal follows the Drug Effectiveness Review Project criteria for osteoporosis biologics. [12]

Manufacturer savings programs. Amgen, Prolia's manufacturer, offers the Amgen FIRST STEP program, which may reduce commercial-plan copays to $0 per injection for eligible members. Medicare beneficiaries are not eligible for manufacturer copay assistance under federal law, but the Extra Help (Low Income Subsidy) program covers Part D drugs. Because Prolia is billed under Part B at KP, Extra Help does not directly apply, but KP Senior Advantage plan design often produces similar savings. [13]

Clinical Criteria That Support a Successful Prior Authorization

Submitting a well-documented PA request is the single most effective way to avoid delays. The clinical record should contain the following elements before the prescriber submits the request.

A recent DXA report (within 24 months) with T-scores at the lumbar spine and left femoral neck is required by virtually every KP regional PA form. The National Osteoporosis Foundation recommends DXA screening for all women aged 65 and older and for younger postmenopausal women with clinical risk factors. [14] A FRAX calculation using the University of Sheffield FRAX tool, with and without bone mineral density, strengthens the clinical justification and is specifically requested in some KP PA forms. [10]

Documentation of fracture history should include radiology reports, not just clinical notes. A vertebral fracture found incidentally on chest or abdominal CT counts as a qualifying fragility fracture under most PA criteria. Vitamin D and calcium status should be documented, including recent 25-OH vitamin D levels, because KP PA reviewers may flag prescriptions for Prolia in the setting of uncorrected severe vitamin D deficiency (<20 ng/mL). [15]

If the patient has contraindications to bisphosphonates, the prescriber should document the specific reason in structured fields: Barrett's esophagus, CKD with eGFR <30, prior bisphosphonate-related osteonecrosis of the jaw, or confirmed intolerance. Renal function labs (serum creatinine and calculated eGFR) should be in the chart, as severe hypocalcemia is a contraindication to Prolia in patients with very low eGFR. [4]

What Happens If Prolia Is Discontinued at Kaiser Permanente?

Stopping Prolia without transitioning to another antiresorptive agent carries a serious, well-documented risk of rapid bone loss and rebound vertebral fractures. The FREEDOM Extension data showed that bone mineral density gains accumulated over 10 years are substantially lost within 12 to 24 months of discontinuation. [16] A 2017 case series published in Osteoporosis International documented multiple vertebral fractures occurring within 7 to 16 months of Prolia discontinuation in patients who had no prior vertebral fracture history. [17]

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "After stopping denosumab, physicians should consider transitioning patients to a bisphosphonate to prevent rapid bone loss and rebound fractures." [18] The standard transition is zoledronic acid 5 mg IV given 6 months after the last Prolia injection, or oral alendronate 70 mg weekly for 12 to 24 months. KP members should not stop Prolia injections simply because of a coverage dispute without consulting their prescriber, as the rebound risk is not theoretical.

If a KP PA is denied and the appeal fails, the prescriber may submit a medical exception request citing the rebound fracture risk if the patient is already established on Prolia. Medical exception language referencing the Endocrine Society guideline and FREEDOM Extension data is often effective. [16] [18]

Alternatives to Prolia That Kaiser Permanente Covers

When Prolia is not approved or is cost-prohibitive, several alternatives are typically covered on KP formularies at lower tiers.

Alendronate (Fosamax generic). Alendronate 70 mg oral tablet weekly is Tier 1 on virtually all KP formularies and costs $0 to $10 per month. The FIT trial (N=2,027) showed alendronate reduced vertebral fracture risk by 47% over 36 months in women with prior vertebral fracture. [19] It is the standard first-line option for most patients without GI contraindications.

Zoledronic acid (Reclast). Zoledronic acid 5 mg IV once yearly is covered under the KP medical benefit. A single infusion reduces vertebral fracture risk by 70% at 3 years per the HORIZON-PFT trial (N=7,765). [20] For patients who cannot take oral medications, this is often the preferred alternative and is typically authorized without a lengthy PA process.

Raloxifene (Evista). Raloxifene 60 mg daily oral tablet is a selective estrogen receptor modulator that reduces vertebral fracture risk by 30 to 50% but has no proven hip fracture benefit. It is Tier 2 on most KP formularies. [21]

Romosozumab (Evenity). Romosozumab is a sclerostin inhibitor given as 210 mg subcutaneous injection monthly for 12 months. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fracture risk by 48% vs. alendronate alone. [22] It carries an FDA black box warning for cardiovascular risk and is reserved for very-high-risk patients. Coverage typically requires even more detailed PA documentation than Prolia.

Teriparatide (Forteo). Teriparatide 20 mcg subcutaneous daily injection is an anabolic agent covered under KP specialty tier. The NEER trial showed 65% reduction in vertebral fractures at 18 months. [23] Cost is substantially higher than Prolia, and PA criteria are strict.

How to Request Prolia Coverage at Kaiser Permanente: Step-by-Step

Navigating the authorization process efficiently reduces delays from weeks to days. Follow this sequence.

First, confirm your plan's current formulary status for Prolia by logging into kp.org, accessing the drug search tool, and entering "denosumab." The formulary listing shows current tier placement and whether PA is required for your specific plan year.

Second, schedule a bone density evaluation if you have not had a DXA within 24 months. Kaiser Permanente facilities perform DXA in-house, and results flow directly into the EHR, simplifying the prescriber's PA submission. The International Society for Clinical Densitometry recommends DXA as the reference standard for fracture risk assessment. [24]

Third, ask your KP endocrinologist or primary care physician to submit the PA with all supporting documentation simultaneously: DXA report, FRAX score, fracture history, renal function, vitamin D level, and contraindication documentation if applicable.

Fourth, if no response is received within 14 days, contact KP Member Services (1-800-464-4000 for California) and request a PA status update. Urgent PA decisions are required within 72 hours under California law for time-sensitive clinical situations. [25]

Fifth, if denied, file a first-level appeal within 60 days of the denial notice. Attach the AACE 2020 guideline excerpt recommending denosumab as first-line for high-fracture-risk patients and the FREEDOM trial summary showing 68% vertebral fracture reduction. [2] [3]

Monitoring Requirements While on Prolia at Kaiser Permanente

KP physicians follow standard monitoring protocols that members should be aware of. Serum calcium should be measured before each injection, particularly in patients with CKD, hypoparathyroidism, or malabsorption syndromes, because hypocalcemia is the most clinically significant acute adverse effect of denosumab. [4] Vitamin D supplementation of at least 1 to 000 IU daily and calcium intake of 1 to 200 mg daily (from diet plus supplement) should be confirmed before each dose per AACE recommendations. [3]

Dental health evaluation before starting Prolia is recommended because osteonecrosis of the jaw, while rare (estimated incidence <1% in osteoporosis patients), is a recognized adverse effect. [26] Annual DXA monitoring is standard practice during Prolia therapy to document treatment response and to guide decisions about duration of therapy. [14]

Atypical femoral fractures are a class effect of antiresorptive agents. Patients should report new thigh or groin pain promptly. The absolute risk remains low: approximately 3.2 to 50 per 100,000 person-years depending on duration of use. [27]